161 related articles for article (PubMed ID: 27731358)
1. A long-acting GH receptor antagonist through fusion to GH binding protein.
Wilkinson IR; Pradhananga SL; Speak R; Artymiuk PJ; Sayers JR; Ross RJ
Sci Rep; 2016 Oct; 6():35072. PubMed ID: 27731358
[TBL] [Abstract][Full Text] [Related]
2. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering.
Yang N; Langenheim JF; Wang X; Jiang J; Chen WY; Frank SJ
Mol Endocrinol; 2008 Apr; 22(4):978-88. PubMed ID: 18096690
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone receptor antagonists therapy for acromegaly.
Parkinson C; Trainer PJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone excess and the development of growth hormone receptor antagonists.
Higham CE; Trainer PJ
Exp Physiol; 2008 Nov; 93(11):1157-69. PubMed ID: 18617577
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
7. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation.
Yang N; Wang X; Jiang J; Frank SJ
Mol Endocrinol; 2007 Jul; 21(7):1642-55. PubMed ID: 17456794
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone and glucose metabolism: the model of the GH-receptor antagonists.
Van der Lely AJ
Ann Endocrinol (Paris); 2004 Feb; 65(1):81-3. PubMed ID: 15122098
[TBL] [Abstract][Full Text] [Related]
9. Short stature in two siblings heterozygous for a novel bioinactive GH mutant (GH-P59S) suggesting that the mutant also affects secretion of the wild-type GH.
Petkovic V; Miletta MC; Boot AM; Losekoot M; Flück CE; Pandey AV; Eblé A; Wit JM; Mullis PE
Eur J Endocrinol; 2013 Mar; 168(3):K35-43. PubMed ID: 23417163
[TBL] [Abstract][Full Text] [Related]
10. Effect of different growth hormone (GH) mutants on the regulation of GH-receptor gene transcription in a human hepatoma cell line.
Deladoëy J; Gex G; Vuissoz JM; Strasburger CJ; Wajnrajch MP; Mullis PE
Eur J Endocrinol; 2002 Apr; 146(4):573-81. PubMed ID: 11916628
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel sites in the ovine growth hormone receptor involved in binding hormone and conferring species specificity.
Allan GJ; Shand JH; Beattie J; Flint DJ
Eur J Biochem; 1999 Apr; 261(2):555-62. PubMed ID: 10215869
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation by growth hormone (GH) of insulin-like growth factor I and GH receptor/binding protein gene expression in rat liver.
Maiter D; Walker JL; Adam E; Moatsstaats B; Mulumba N; Ketelslegers JM; Underwood LE
Endocrinology; 1992 Jun; 130(6):3257-64. PubMed ID: 1375898
[TBL] [Abstract][Full Text] [Related]
13. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
14. Insulin receptor substrate-1 enhances growth hormone-induced proliferation.
Liang L; Zhou T; Jiang J; Pierce JH; Gustafson TA; Frank SJ
Endocrinology; 1999 May; 140(5):1972-83. PubMed ID: 10218944
[TBL] [Abstract][Full Text] [Related]
15. The place of pegvisomant in the management of acromegaly.
Parkinson C; Trainer PJ
Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
[TBL] [Abstract][Full Text] [Related]
16. Reduced proteolysis of rabbit growth hormone (GH) receptor substituted with mouse GH receptor cleavage site.
Wang X; He K; Gerhart M; Jiang J; Paxton RJ; Menon RK; Black RA; Baumann G; Frank SJ
Mol Endocrinol; 2003 Oct; 17(10):1931-43. PubMed ID: 12829808
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of a novel, orally bioavailable, small molecule growth hormone receptor antagonist.
Rosengren L; Parrow V; Chmielewska J; Mode A; Fhölenhag K
Growth Horm IGF Res; 2007 Feb; 17(1):47-53. PubMed ID: 17161642
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological therapy for acromegaly: a critical review.
Muller AF; Van Der Lely AJ
Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
[TBL] [Abstract][Full Text] [Related]
19. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
